Screening & Prevention — MCQs
On this page
A 58-year-old man with a BMI of 43 kg/m², type 2 diabetes, hypertension, and obstructive sleep apnoea attends for weight management review. Despite 9 months of intensive lifestyle intervention and maximum tolerated dose of orlistat, his weight has decreased from 142 kg to 138 kg (2.8% weight loss). His HbA1c has increased from 64 to 71 mmol/mol. What is the most appropriate next step?
A 41-year-old woman presents requesting cardiovascular risk assessment. Her father died aged 46 of myocardial infarction, and her brother was diagnosed with familial hypercholesterolaemia. Her total cholesterol is 8.2 mmol/L, LDL 6.1 mmol/L, triglycerides 1.8 mmol/L. Her QRISK3 score calculates as 8.5%. What is the most appropriate management approach?
A 71-year-old woman with type 2 diabetes for 12 years is noted to have missed her last two diabetic retinopathy screening appointments. She explains she doesn't attend because her vision is fine and she sees her optician annually. Her most recent HbA1c is 68 mmol/mol. What is the most important point to explain about diabetic eye screening?
A 56-year-old woman attends for discussion about smoking cessation. She smokes 20 cigarettes daily and has a 35 pack-year history. She has tried nicotine replacement therapy twice without success. She has no contraindications to pharmacological treatment. Which medication combination offers the highest quit rates for smoking cessation?
A 69-year-old man attends for discussion of his NHS Health Check results. He has a QRISK3 score of 18%, total cholesterol 6.8 mmol/L, HDL 1.1 mmol/L, blood pressure 148/92 mmHg, BMI 29 kg/m², and HbA1c 41 mmol/mol. He is a non-smoker. What is the most appropriate initial management strategy?
A 32-year-old woman with learning disabilities attends with her carer for cervical screening. She has capacity to consent but becomes very anxious during speculum examination and the test cannot be completed. What is the most appropriate next step in her management?
A 63-year-old woman attends for her NHS breast screening appointment. She asks about the frequency of mammographic screening in the NHS Breast Screening Programme. What is the standard screening interval for women aged 50-70 years in England?
What is the age range for men eligible for NHS Abdominal Aortic Aneurysm (AAA) screening programme in England?
A 70-year-old man with type 2 diabetes for 18 years attends for review. His most recent diabetic retinopathy screening (6 months ago) was graded as R1M1 (background retinopathy and maculopathy). He has now developed blurred vision in his right eye over the past week. Visual acuity is 6/18 in the right eye (previously 6/9) and 6/6 in the left eye. Fundoscopy shows dot and blot haemorrhages consistent with his previous screening result. What is the most appropriate management?
A 38-year-old man presents for cardiovascular risk assessment. His father died suddenly at age 42 from myocardial infarction, and his paternal grandfather died at age 45 from heart disease. Lipid profile shows: total cholesterol 8.9 mmol/L, LDL 6.8 mmol/L, HDL 1.1 mmol/L, triglycerides 1.8 mmol/L. On examination, he has bilateral Achilles tendon thickening and tendon xanthomata. What is the most appropriate immediate management?
Screening & Prevention UK Medical PG Practice Questions and MCQs
Question 81: A 58-year-old man with a BMI of 43 kg/m², type 2 diabetes, hypertension, and obstructive sleep apnoea attends for weight management review. Despite 9 months of intensive lifestyle intervention and maximum tolerated dose of orlistat, his weight has decreased from 142 kg to 138 kg (2.8% weight loss). His HbA1c has increased from 64 to 71 mmol/mol. What is the most appropriate next step?
- A. Continue current management and review in 6 months
- B. Refer to tier 3 weight management service for consideration of pharmacotherapy or bariatric surgery (Correct Answer)
- C. Switch from orlistat to liraglutide for dual diabetes and weight management
- D. Increase diabetes medication and continue lifestyle modification
- E. Arrange psychological assessment for possible eating disorder
Explanation: ***Refer to tier 3 weight management service for consideration of pharmacotherapy or bariatric surgery*** - The patient's **BMI of 43 kg/m²** and failure to achieve significant weight loss (only 2.8% after 9 months) with intensive lifestyle and orlistat, along with worsening **HbA1c**, meet the **NICE criteria** for referral to specialist (tier 3 or 4) weight management services. - A specialist service can offer a **multidisciplinary assessment** and consider advanced interventions like **bariatric surgery** or other **pharmacotherapy** (e.g., GLP-1 receptor agonists) under expert guidance, which are appropriate given his complex comorbidities like **Type 2 Diabetes** and **Obstructive Sleep Apnea**. *Continue current management and review in 6 months* - **Orlistat** is typically discontinued if at least **5% weight loss** is not achieved within 3 months, making continued current management after 9 months of poor results inappropriate and ineffective. - His worsening **HbA1c** indicates a progressive metabolic issue that requires more aggressive intervention, not a delayed review with an ineffective regimen. *Switch from orlistat to liraglutide for dual diabetes and weight management* - While **liraglutide** (a GLP-1 receptor agonist) is effective for both diabetes and weight loss, the patient's severe obesity (BMI 43 kg/m²) and failure of primary care interventions warrant a comprehensive evaluation by a **tier 3 specialist service**. - A specialist service can provide a holistic approach, considering all suitable pharmacotherapy options and multidisciplinary support, rather than a single medication switch in primary care. *Increase diabetes medication and continue lifestyle modification* - Simply increasing **diabetes medication** addresses the symptom (hyperglycemia) but not the underlying cause of severe obesity, which is driving his metabolic deterioration. - The patient has already undergone **intensive lifestyle modification** for 9 months with minimal success, so continuing this without further escalation is unlikely to be effective in preventing further glycemic decline or achieving meaningful weight loss. *Arrange psychological assessment for possible eating disorder* - There is no specific information in the patient's history, such as **binge eating episodes**, purging, or distorted body image, to primarily suggest an **eating disorder** as the immediate next step. - While psychological support is crucial in weight management, it is typically part of the multidisciplinary assessment within a **tier 3 weight management service**, rather than a standalone assessment for an eating disorder at this stage.
Question 82: A 41-year-old woman presents requesting cardiovascular risk assessment. Her father died aged 46 of myocardial infarction, and her brother was diagnosed with familial hypercholesterolaemia. Her total cholesterol is 8.2 mmol/L, LDL 6.1 mmol/L, triglycerides 1.8 mmol/L. Her QRISK3 score calculates as 8.5%. What is the most appropriate management approach?
- A. Start atorvastatin 20 mg as QRISK3 is approaching 10% threshold
- B. Do not use QRISK3; offer lipid specialist referral and start high-intensity statin (Correct Answer)
- C. Start atorvastatin 80 mg and repeat lipids in 3 months
- D. Arrange genetic testing for familial hypercholesterolaemia before treatment
- E. Provide intensive lifestyle advice and reassess QRISK3 in 12 months
Explanation: ***Do not use QRISK3; offer lipid specialist referral and start high-intensity statin*** - **QRISK3** is not intended for use and underestimates risk in patients with suspected **familial hypercholesterolaemia (FH)** due to lifelong cholesterol exposure. - This patient meets criteria for suspected FH (Total Cholesterol >7.5 mmol/L and premature family history); management requires **specialist referral** and immediate **high-intensity statin** therapy. *Start atorvastatin 20 mg as QRISK3 is approaching 10% threshold* - **20 mg atorvastatin** is a primary prevention dose for general populations; patients with FH require more potent **high-intensity** regimens. - Relying on the **10% QRISK3 threshold** is inappropriate here as the tool is invalidated for patients with strongly suspected genetic dyslipidemias. *Start atorvastatin 80 mg and repeat lipids in 3 months* - While **80 mg atorvastatin** is the correct high-intensity treatment, this option fails to address the essential requirement for **specialist referral** and cascade testing. - FH management is not limited to statin initiation; it involves **clinical scoring** (Simon Broome) and formal risk assessment by experts. *Arrange genetic testing for familial hypercholesterolaemia before treatment* - **Genetic testing** is often performed by specialists, but pharmacological treatment should not be delayed while awaiting these results. - Immediate **lipid-lowering therapy** is prioritized to reduce the significant risk of premature **myocardial infarction**. *Provide intensive lifestyle advice and reassess QRISK3 in 12 months* - **Lifestyle advice** is insufficient for FH as the condition is driven by genetic defects that prevent adequate clearance of **LDL cholesterol**. - Delaying treatment for 12 months increases the risk of **major adverse cardiovascular events** in a high-risk patient.
Question 83: A 71-year-old woman with type 2 diabetes for 12 years is noted to have missed her last two diabetic retinopathy screening appointments. She explains she doesn't attend because her vision is fine and she sees her optician annually. Her most recent HbA1c is 68 mmol/mol. What is the most important point to explain about diabetic eye screening?
- A. Optician examinations cannot replace NHS diabetic eye screening as they don't routinely dilate pupils
- B. Diabetic retinopathy causes visual symptoms early, allowing time for intervention
- C. Annual screening is only required if HbA1c is suboptimal or duration exceeds 10 years
- D. Sight-threatening diabetic retinopathy can develop without symptoms and requires digital retinal photography (Correct Answer)
- E. Diabetic eye screening can be deferred if recent cataract surgery was performed
Explanation: ***Sight-threatening diabetic retinopathy can develop without symptoms and requires digital retinal photography***- **Diabetic retinopathy** is notoriously **asymptomatic** in its early, treatable stages, meaning a patient's self-reported "fine vision" is not a reliable indicator of eye health.- Specialized **digital retinal photography** is the gold standard for screening to detect **microaneurysms**, hemorrhages, and exudates before they cause irreversible vision loss.*Optician examinations cannot replace NHS diabetic eye screening as they don't routinely dilate pupils*- While **optician exams** provide general checks, they lack the **standardized grading** and systematic reporting used by the national screening program to monitor progression.- The distinction regarding **pupil dilation** is secondary to the fact that optician records are not integrated into the specialist **diabetic clinical pathway**.*Diabetic retinopathy causes visual symptoms early, allowing time for intervention*- This is medically incorrect; visual symptoms such as **blurring** or **floaters** usually only occur once **maculopathy** or **proliferative disease** has already developed.- Intervention is most effective when the disease is **pre-symptomatic**, making regular screening vital regardless of visual acuity.*Annual screening is only required if HbA1c is suboptimal or duration exceeds 10 years*- All patients with diabetes are at risk; although **poor glycemic control** (HbA1c > 58 mmol/mol) increases risk, screening is mandated for **all individuals** with diabetes from age 12.- Current guidelines require regular screening (usually **annually**) even if the patient has had the condition for less than 10 years.*Diabetic eye screening can be deferred if recent cataract surgery was performed*- **Cataract surgery** does not treat or prevent **diabetic retinopathy**; in fact, the inflammatory stress of surgery can occasionally exacerbate underlying retinal issues.- Patients must remain in the **screening program** regardless of other ophthalmological procedures to monitor for **vascular changes**.
Question 84: A 56-year-old woman attends for discussion about smoking cessation. She smokes 20 cigarettes daily and has a 35 pack-year history. She has tried nicotine replacement therapy twice without success. She has no contraindications to pharmacological treatment. Which medication combination offers the highest quit rates for smoking cessation?
- A. Varenicline alone
- B. Bupropion alone
- C. Nicotine patch plus nicotine gum dual therapy
- D. Varenicline plus nicotine patch combination (Correct Answer)
- E. Bupropion plus nicotine replacement therapy
Explanation: ***Varenicline plus nicotine patch combination*** - Combining **Varenicline** with a **long-acting nicotine patch** is clinically proven to achieve higher cessation rates than monotherapy by reducing both cravings and withdrawal symptoms. - This approach is particularly effective in heavy smokers with a significant **pack-year history** who have previously failed single-agent therapies. *Varenicline alone* - While **Varenicline monotherapy** is more effective than Bupropion or single-form NRT, it is statistically inferior to its combination with **nicotine replacement therapy (NRT)**. - It acts as a **partial agonist** at the α4β2 nicotinic acetylcholine receptor, but adding a patch provides better relief during the initial cessation phase. *Bupropion alone* - **Bupropion** is an antidepressant that inhibits the reuptake of dopamine and norepinephrine, but it generally has **lower quit rates** compared to Varenicline. - It is often reserved as a second-line option or for patients with specific contraindications to **Varenicline** or with co-morbid depression. *Nicotine patch plus nicotine gum dual therapy* - **Dual NRT** (patch plus a short-acting form like gum) is superior to single NRT but is typically less effective than **Varenicline-based combinations**. - This patient specifically noted a lack of success with previous **NRT attempts**, suggesting a need for a more potent pharmacological intervention. *Bupropion plus nicotine replacement therapy* - The combination of **Bupropion and NRT** provides higher success rates than Bupropion alone but remains less effective than **Varenicline-NRT** regimens. - Recent evidence and guidelines favor Varenicline as the backbone for **combination therapy** in high-dependency smokers.
Question 85: A 69-year-old man attends for discussion of his NHS Health Check results. He has a QRISK3 score of 18%, total cholesterol 6.8 mmol/L, HDL 1.1 mmol/L, blood pressure 148/92 mmHg, BMI 29 kg/m², and HbA1c 41 mmol/mol. He is a non-smoker. What is the most appropriate initial management strategy?
- A. Start atorvastatin 20 mg and arrange blood pressure monitoring (Correct Answer)
- B. Arrange repeat HbA1c in 3 months and lifestyle advice only
- C. Start atorvastatin 80 mg, amlodipine 5 mg, and metformin
- D. Provide lifestyle advice and reassess cardiovascular risk in 12 months
- E. Refer to cardiology for specialist cardiovascular risk assessment
Explanation: ***Start atorvastatin 20 mg and arrange blood pressure monitoring*** - The patient's **QRISK3 score of 18%** is significantly above the **10% threshold** (NICE guidelines) for initiating primary prevention with a statin, making **atorvastatin 20 mg** the appropriate starting dose. - A clinic blood pressure of **148/92 mmHg** suggests **Stage 1 hypertension**; this needs confirmation with **Ambulatory Blood Pressure Monitoring (ABPM)** or Home Blood Pressure Monitoring (HBPM) before commencing antihypertensive medication. *Arrange repeat HbA1c in 3 months and lifestyle advice only* - An **HbA1c of 41 mmol/mol** is within the normal range, or just at the very upper end of normal (pre-diabetes is typically 42-47 mmol/mol), so repeating it in 3 months is not the immediate priority over managing high cardiovascular risk. - Relying solely on lifestyle advice ignores the patient's **high QRISK3 score (18%)**, which necessitates immediate pharmacological intervention with a statin. *Start atorvastatin 80 mg, amlodipine 5 mg, and metformin* - **Atorvastatin 80 mg** is a higher dose usually reserved for **secondary prevention** or very high-risk primary prevention, not typically as an initial dose for a QRISK3 score of 18%. - **Metformin** is indicated for type 2 diabetes, which the patient does not have (**HbA1c 41 mmol/mol**), and **amlodipine** should not be started without confirmed hypertension via **ABPM/HBPM**. *Provide lifestyle advice and reassess cardiovascular risk in 12 months* - For a patient with a **QRISK3 score of 18%**, delaying pharmacological intervention for 12 months is inappropriate and unsafe, as it leaves them at significant immediate risk of cardiovascular events. - While **lifestyle advice** is crucial, it is insufficient on its own for this level of risk and must be combined with statin therapy. *Refer to cardiology for specialist cardiovascular risk assessment* - The assessment and initial management of cardiovascular risk using tools like **QRISK3** fall within the scope of **primary care**. - Specialist cardiology referral is typically reserved for complex cases, such as suspected **familial hypercholesterolaemia** (e.g., total cholesterol > 7.5 mmol/L or specific family history) or established complex heart disease, which are not indicated here.
Question 86: A 32-year-old woman with learning disabilities attends with her carer for cervical screening. She has capacity to consent but becomes very anxious during speculum examination and the test cannot be completed. What is the most appropriate next step in her management?
- A. Document failed attempt and inform her she cannot have screening
- B. Arrange repeat attempt in 6 months with practice nurse
- C. Offer hrHPV self-sampling as an alternative to speculum examination (Correct Answer)
- D. Refer to colposcopy for examination under general anaesthetic
- E. Prescribe diazepam for sedation prior to next screening attempt
Explanation: ***Offer hrHPV self-sampling as an alternative to speculum examination*** - This option directly addresses the patient's **anxiety** and inability to tolerate the **speculum examination**, providing an effective and less invasive alternative for cervical screening. - **hrHPV self-sampling** allows individuals, especially those with learning disabilities or severe anxiety, to collect their own sample for HPV testing, promoting **equitable access** to screening.*Document failed attempt and inform her she cannot have screening* - This is an **unacceptable** approach as it denies the patient her right to **preventive healthcare** and fails to make reasonable adjustments for her disability. - Healthcare providers have a duty to ensure **accessible services** and explore all possible alternatives to facilitate screening for vulnerable patients.*Arrange repeat attempt in 6 months with practice nurse* - A simple repeat attempt without addressing the underlying issue of **speculum intolerance** is unlikely to be successful and may exacerbate the patient's **anxiety**. - This approach fails to provide a **patient-centered solution** and is inefficient given the identified barrier.*Refer to colposcopy for examination under general anaesthetic* - **Examination under general anaesthetic (EUA)** is an invasive procedure with inherent risks and is generally reserved for diagnostic or therapeutic interventions, not routine **primary screening**. - This option is **overly aggressive** and disproportionate as a first-line alternative, especially when less invasive and equally effective screening methods are available.*Prescribe diazepam for sedation prior to next screening attempt* - While sedation might reduce anxiety, it carries risks such as **oversedation**, **adverse drug reactions**, and requires careful monitoring, which complicates a routine screening procedure. - Providing **hrHPV self-sampling** is a more empowering, patient-friendly, and non-pharmacological solution that avoids the potential side effects and logistical challenges of sedation.
Question 87: A 63-year-old woman attends for her NHS breast screening appointment. She asks about the frequency of mammographic screening in the NHS Breast Screening Programme. What is the standard screening interval for women aged 50-70 years in England?
- A. Annually
- B. Every 18 months
- C. Every 2 years
- D. Every 3 years (Correct Answer)
- E. Every 5 years
Explanation: ***Every 3 years*** - The **NHS Breast Screening Programme** in England invites women aged **50 to 70** for mammographic screening at a standard interval of **every three years**. - This interval is designed to balance the **early detection** of breast cancer with minimizing **over-diagnosis** and unnecessary **radiation exposure**. *Annually* - **Annual screening** is not the standard for the general population in the UK due to concerns about increased **false positives** and cumulative **radiation exposure**. - Annual mammograms are typically reserved for women at **very high risk**, such as those with specific genetic mutations like **BRCA1 or BRCA2**. *Every 18 months* - An **18-month interval** is not currently utilized within the UK national breast screening program for any demographic or risk category. - This frequency has not been demonstrated to offer a significant clinical advantage over the established **triennial** (three-yearly) approach for the general population. *Every 2 years* - While a **two-year interval** is common in several other international screening programs, it is not the protocol for the **NHS in England**. - The UK system adheres to its **three-year cycle**, though women over 70 can continue to **self-refer** for screening at the same frequency. *Every 5 years* - A **five-year interval** is considered too extended for effective breast cancer screening, as aggressive cancers could develop and advance significantly between appointments. - This longer frequency would substantially reduce the program's efficacy in identifying **asymptomatic cancers** at an early, more treatable stage.
Question 88: What is the age range for men eligible for NHS Abdominal Aortic Aneurysm (AAA) screening programme in England?
- A. All men aged 60-74 years
- B. Men aged 65 years invited in the year they turn 65 (Correct Answer)
- C. All men aged 50-65 years
- D. Men aged 65-70 years
- E. All men over 60 years on initial invitation
Explanation: ***Men aged 65 years invited in the year they turn 65***- The **NHS Abdominal Aortic Aneurysm (AAA) screening programme** in England specifically invites all men for a one-off **ultrasound scan** in the year they turn **65**.- This age is chosen to identify clinically significant aneurysms, balancing the **prevalence** of AAA with the **cost-effectiveness** and benefit of early detection to prevent rupture.*All men aged 60-74 years*- This age range is too broad and not specific to the **single invitation** nature of the AAA screening program.- Other screening programs, like **Bowel Cancer Screening**, might use broader age ranges for repeated invitations, but AAA screening is a one-time event at a particular age.*All men aged 50-65 years*- Screening at age 50 is too early, as the **prevalence** of clinically significant AAAs is much lower in this younger cohort, making screening less efficient.- The **NHS AAA screening programme** specifically targets men in their **65th year** to optimize detection rates and clinical benefit.*Men aged 65-70 years*- While men over 65 who missed their initial invitation can **self-refer**, the primary **routine invitation** for the NHS AAA screening is strictly for men in the year they turn **65**.- There isn't a continuous automatic invitation window between 65 and 70; the initial screening is a one-off event.*All men over 60 years on initial invitation*- The initial invitation is precisely targeted at **65 years** of age, not broadly for all men over 60.- Men older than 65 who have not been screened need to **proactively contact** the screening service, as they won't receive an automatic invitation after turning 65.
Question 89: A 70-year-old man with type 2 diabetes for 18 years attends for review. His most recent diabetic retinopathy screening (6 months ago) was graded as R1M1 (background retinopathy and maculopathy). He has now developed blurred vision in his right eye over the past week. Visual acuity is 6/18 in the right eye (previously 6/9) and 6/6 in the left eye. Fundoscopy shows dot and blot haemorrhages consistent with his previous screening result. What is the most appropriate management?
- A. Refer urgently to ophthalmology for assessment within 1 week (Correct Answer)
- B. Reassure and arrange routine annual diabetic retinopathy screening
- C. Optimize glycaemic control and arrange repeat screening in 3 months
- D. Refer to optometry for refraction and new spectacles
- E. Arrange urgent same-day ophthalmology assessment
Explanation: ***Refer urgently to ophthalmology for assessment within 1 week*** - Any diabetic patient experiencing **acute visual deterioration**, such as this patient's decline from 6/9 to 6/18, requires **urgent specialist review** regardless of previous screening results. - The presence of **M1 (maculopathy)** increases the risk of rapid progression to **diabetic macular oedema**, which can lead to irreversible sight loss if not managed promptly. *Reassure and arrange routine annual diabetic retinopathy screening* - **Routine screening** is only appropriate for asymptomatic patients with stable findings; it is unsafe for a patient with **new-onset blurred vision**. - Waiting for annual screening ignores the **red flag** of a significant drop in **visual acuity**, potentially leading to permanent blindness. *Optimize glycaemic control and arrange repeat screening in 3 months* - While **glycaemic control** is vital for long-term management, it will not address the acute pathology causing the **current vision loss**. - A **3-month delay** is too long for a patient showing active symptoms of **macular involvement**, as treatment efficacy decreases with time. *Refer to optometry for refraction and new spectacles* - This approach incorrectly assumes a **refractive error** rather than addressing the known **diabetic retinopathy** and maculopathy complications. - **Dot and blot haemorrhages** and sudden blurring indicate organic disease that **optometry** cannot treat with glasses. *Arrange urgent same-day ophthalmology assessment* - **Same-day referral** is typically reserved for **sudden-onset sight loss** (e.g., vitreous haemorrhage) or emergencies like **retinal detachment** or acute glaucoma. - While the patient's condition is urgent, a review **within 1 week** is the standard clinical guideline for subacute visual changes in diabetic maculopathy.
Question 90: A 38-year-old man presents for cardiovascular risk assessment. His father died suddenly at age 42 from myocardial infarction, and his paternal grandfather died at age 45 from heart disease. Lipid profile shows: total cholesterol 8.9 mmol/L, LDL 6.8 mmol/L, HDL 1.1 mmol/L, triglycerides 1.8 mmol/L. On examination, he has bilateral Achilles tendon thickening and tendon xanthomata. What is the most appropriate immediate management?
- A. Calculate QRISK3 score and start atorvastatin 20mg if >10%
- B. Start atorvastatin 80mg and refer to specialist lipid clinic (Correct Answer)
- C. Arrange genetic testing for familial hypercholesterolaemia before starting treatment
- D. Refer to specialist lipid clinic and defer statin therapy until specialist review
- E. Start atorvastatin 20mg and titrate according to response, aiming for 40% reduction in non-HDL cholesterol
Explanation: ***Start atorvastatin 80mg and refer to specialist lipid clinic***- This patient presents with classical features of **familial hypercholesterolaemia (FH)**, including markedly elevated **LDL cholesterol** (6.8 mmol/L), a strong family history of premature **coronary artery disease** (father and grandfather dying at young ages), and diagnostic physical signs such as **Achilles tendon thickening** and **tendon xanthomata**.- **NICE guidelines** recommend immediate initiation of a **high-intensity statin** (e.g., atorvastatin 80mg) to aggressively lower LDL and mitigate the significant **lifetime cardiovascular risk** associated with FH, coupled with a prompt **referral to a specialist lipid clinic** for further management and cascade screening.*Calculate QRISK3 score and start atorvastatin 20mg if >10%*- **QRISK3** and similar cardiovascular risk calculators are designed for the general population and significantly **underestimate** the true risk in patients with established or highly suspected conditions like **familial hypercholesterolaemia**.- The patient's clinical presentation, including markedly elevated **LDL** and **tendon xanthomata**, already indicates an extremely high cardiovascular risk, rendering a QRISK3 calculation unnecessary and a low-dose statin (20mg) inadequate for initial management.*Arrange genetic testing for familial hypercholesterolaemia before starting treatment*- While **genetic testing** is a valuable tool for confirming **familial hypercholesterolaemia** and facilitating **cascade screening** of relatives, it should **not delay** the immediate initiation of life-saving lipid-lowering therapy.- Treatment is commenced based on robust clinical criteria (such as very high LDL and tendon xanthomata), and genetic testing can proceed in parallel without deferring critical intervention.*Refer to specialist lipid clinic and defer statin therapy until specialist review*- Deferring statin therapy is inappropriate and potentially dangerous given the patient's extremely high risk of a **premature cardiovascular event**, highlighted by his father's death at age 42, which is highly indicative of FH.- Primary care should initiate **high-intensity statins** immediately upon clinical suspicion of FH, typically **atorvastatin 80mg**, without waiting for the specialist appointment to avoid delay in crucial risk reduction.*Start atorvastatin 20mg and titrate according to response, aiming for 40% reduction in non-HDL cholesterol*- A starting dose of **atorvastatin 20mg** is standard for primary prevention in the general population but is generally considered insufficient for the aggressive management required in **familial hypercholesterolaemia**.- Patients with FH require **maximal tolerated doses of high-intensity statins** (e.g., atorvastatin 80mg) from the outset to achieve optimal reductions in **LDL cholesterol** and effectively manage their very high lifetime cardiovascular risk.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free